This accumulation correlated with growth arrest, apoptosis, and cell differentiation in AML cell lines and primary AML cells, emphasizing the potential of combining AKR1C3 inhibitors with established therapies for enhanced outcomes (Murray et al., 2010). The gene discussed is AKR1C3; the disease is acute myeloid leukemia.